^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sabestomig (AZD7789)

    i
    Other names: AZD7789, AZD 7789, AZD-7789
    Associations

    News

    Trials
    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor, TIM-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    D9571C00001: Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=45, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    sabestomig (AZD7789)
    3ms
    TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=165, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=371 --> 165 | Trial completion date: Jan 2026 --> Apr 2026 | Trial primary completion date: Jan 2026 --> Apr 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    carboplatin • Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    5ms
    GEMINI-Gastric: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=240, Recruiting, AstraZeneca | Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Jan 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    11ms
    GEMINI-Gastric: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=240, Recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    12ms
    D9571C00001: Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, AstraZeneca | Phase classification: P1/2 --> P1
    Phase classification
    |
    sabestomig (AZD7789)
    12ms
    A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (clinicaltrials.gov)
    P1/2, N=136, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=232 --> 136 | Trial primary completion date: Aug 2026 --> Dec 2024
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    PD-L1 expression
    |
    sabestomig (AZD7789)
    1year
    D9571C00001: Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    sabestomig (AZD7789)
    over1year
    D9571C00001: Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, AstraZeneca | Trial completion date: Oct 2027 --> Dec 2024 | Trial primary completion date: Feb 2026 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    sabestomig (AZD7789)
    over1year
    A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (clinicaltrials.gov)
    P1/2, N=232, Recruiting, AstraZeneca | Trial completion date: Jul 2025 --> Aug 2026 | Trial primary completion date: Jul 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    sabestomig (AZD7789)
    over1year
    Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=180 --> 45 | Trial primary completion date: Aug 2026 --> Feb 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    sabestomig (AZD7789)
    over1year
    MST01-AZN-05: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov)
    P1, N=15, Recruiting, Presage Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    over1year
    PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Presage Biosciences
    New P1 trial
    |
    Keytruda (pembrolizumab) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)